Melanoma and squamous cell carcinoma of the head and neck research hub

Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

This study is looking at a new treatment before and after surgery for certain skin cancers and head and neck cancers. It combines two new drugs (IO102-IO103) with an existing cancer drug (Keytruda) to see how effectively they shrink tumors and improve patient outcomes.